Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

HighVista increased its Tyra Biosciences stake by 96,218 shares in the first quarter, representing an estimated $3.11 million purchase based on quarterly average prices. The filing reflects a modest increase in institutional exposure to the biotech name, but it does not include operating or clinical updates. Market impact is likely limited and primarily relevant for sentiment and positioning.

Analysis

HighVista increased its Tyra Biosciences stake by 96,218 shares in the first quarter, representing an estimated $3.11 million purchase based on quarterly average prices. The filing reflects a modest increase in institutional exposure to the biotech name, but it does not include operating or clinical updates. Market impact is likely limited and primarily relevant for sentiment and positioning.